CN103027905A - Use of arctigenin in preparing drug for treating synovitis - Google Patents

Use of arctigenin in preparing drug for treating synovitis Download PDF

Info

Publication number
CN103027905A
CN103027905A CN2012103699790A CN201210369979A CN103027905A CN 103027905 A CN103027905 A CN 103027905A CN 2012103699790 A CN2012103699790 A CN 2012103699790A CN 201210369979 A CN201210369979 A CN 201210369979A CN 103027905 A CN103027905 A CN 103027905A
Authority
CN
China
Prior art keywords
arctigenin
synovitis
preparation
purposes
liniment
Prior art date
Application number
CN2012103699790A
Other languages
Chinese (zh)
Inventor
赵志全
徐真真
关永霞
Original Assignee
鲁南制药集团股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201110301017.7 priority Critical
Priority to CN201110301017 priority
Application filed by 鲁南制药集团股份有限公司 filed Critical 鲁南制药集团股份有限公司
Priority to CN2012103699790A priority patent/CN103027905A/en
Publication of CN103027905A publication Critical patent/CN103027905A/en

Links

Abstract

The invention belongs to the field of medicines, and in particular relates to a use of arctigenin in preparing a drug for treating synovitis. The arctigenin preparation provided by the invention has a definite curative effect, a rapid effect and low toxicity in treating synovitis, is convenient to use, and has a good clinical application prospect.

Description

The purposes of arctigenin in preparation treatment synovitis medicine

Technical field

The invention belongs to field of medicaments, be specifically related to the purposes of arctigenin in preparation treatment synovitis medicine.

Background technology

(English name: synovitis), be a kind of multiple diseases, its site of pathological change is mainly in knee joint for synovitis.Knee joint is that the human body synovial membrane is maximum, articular surface maximum and the most complicated joint of structure, because the knee joint synovial membrane is extensive and be positioned at the limbs table than the superficial part position, therefore the chance of being damaged and infecting is more, gonarthromeningitis mainly is because of sprain of knee joint and multiple intraarticular damage, and the one group of syndrome that causes easily causes the temporary transient or long-term part disability of patient, to patient and all larger to the harm of society.

Treat clinically at present the synovitis method varied, curative effect is different.Mainly contain the external application Chinese medicine powder and guarantee to cure treatment, massage therapy, puncture therapy, Drug therapy, traditional Chinese medical science plaster therapy, fixing and do exercises therapy and composite treatment etc.Wherein the external application Chinese medicine powder guarantees to cure that to treat the synovitis curative effect thorough, and its advantage is, relies on the direct osmosis of external, need not be oral, do not absorb by stomach, so hinder less than liver, gallbladder, spleen, kidney etc., easy to use, be free from side effects, effect a radical cure effect from pathology very desirable.

Zhou Yucang is at " Fructus Arctii Decoction treatment spleen emptiness and wet sputum type kneecap articular synovitis " (TCM Document magazine, the 2nd phase in 2008: 44-45) disclose and external application for curing kneecap articular synovitis for oral administration with Fructus Arctii Decoction, analyze the clinical data of 50 routine gonarthromeningitis treatments, wherein fully recover 10 examples, produce effects 20 examples, take a turn for the better 12 examples, invalid 8 examples, total effective rate 84%.Therefore, for oral administration and external application of Fructus Arctii Decoction is a kind of simple, the economic Therapeutic Method effectively again for the treatment of kneecap articular synovitis.

Zhang Jiebiao discloses with Fructus Arctii Decoction at " Fructus Arctii Decoction cooperates traction therapeutic children's hip periostitis 26 examples " (Sichuan traditional Chinese medical science .1996,14 (4) .-48-48) and has cooperated traction therapeutic children's hip periostitis determined curative effect.

Fructus Arctii is the dry mature fruit of feverfew Fructus Arctii, is conventional Chinese medicine, has the function of dispelling wind and heat pathogens, lung qi dispersing rash, resolving toxin and disinhibiting the throat, is used for anemopyretic cold, cough with copious phlegm, measles, rubella, laryngopharynx swelling and pain, itch cheek erysipelas, carbuncle sore tumefacting virus.This Chinese medicine contains Lignanoids compounds, mainly is Arctiin (arctiin) and arctigenin (arctigenin) etc.Although the content of arctigenin in Fructus Arctii is very low, its precursor Arctiin content in Chinese medicine Fructus Arctii and burr Fructus Arctii fruit is higher, so can obtain a large amount of arctigenins by the Arctiin conversion.According to the literature, Arctiin is broken down into arctigenin in vivo and produces numerous pharmacological actions, and arctigenin has stronger biological activity than Arctiin.

Summary of the invention

The invention provides the purposes of a kind of arctigenin in preparation treatment synovitis medicine, arctigenin is when being used for such use, can make suitable arctigenin preparation administration, wherein said arctigenin preparation is preferably the external preparation that comprises arctigenin, and described arctigenin external preparation can be liniment, transdermal patch, spray, ointment, gel, aerosol or ointment.

For achieving the above object, the present invention takes following technical scheme:

Arctigenin liniment provided by the invention, glycerol is as wetting agent, carbamide is as penetration enhancer, benzalkonium bromide is as antiseptic, three kinds of material couplings absorb administration by local skin, are conducive to skin and absorb, local drug concentration that can the Effective Raise allergic skin, and the plasma protein binding rate of arctigenin reaches more than 93% its therapeutical effect of more efficiently performance.

Comprise arctigenin, glycerol, carbamide, benzalkonium bromide, sodium chloride and water in the arctigenin liniment prescription provided by the invention.The present invention screens the proportioning of arctigenin, glycerol, carbamide, benzalkonium bromide and five kinds of compositions of sodium chloride in the arctigenin liniment prescription.Preferably, the weight portion of arctigenin, glycerol, carbamide, benzalkonium bromide, five kinds of compositions of sodium chloride is in the arctigenin liniment prescription:

The arctigenin liniment is comprised of the water (such as 100ml) according to arctigenin, glycerol, carbamide, benzalkonium bromide and five kinds of components of sodium chloride and the certain volume of said ratio.

Arctigenin transdermal patch provided by the invention comprises backing layer, drug storage layer and adhered layer, it is characterized in that the weight portion of each component of drug storage layer is:

Arctigenin 1-10, phosphatidase 15-10, cholesterol 2-10, carbomer 1-10, buffer 200-1000, sodium polyacrylate 2-10, glycerol 10-100, vitamin E 0.1-1.0.

The preparation method of each component of above-mentioned arbitrary mix proportion scheme being made the transdermal patch for the treatment of synovitis of the present invention is:

The preparation of a, liposome: take by weighing recipe quantity arctigenin, fabaceous lecithin, cholesterol, vitamin E, dissolving adds diethyl ether; Other gets phosphate buffer, be heated to 40-80 ℃ and keep constant temperature, prepared diethyl ether solution is at the uniform velocity injected buffer under the continuous stirring, continued to stir after ether is waved to the greatest extent supersound process 10-60 minute, make milky arctigenin liposome turbid liquor.

The preparation of b, drug gel: get carbomer, sodium polyacrylate, glycerol, moistening grinds well, and in the arctigenin liposome turbid liquor that adding a makes, stirs and makes its swelling, transfers PH to 5-7, continues to stir, and makes the arctigenin lipidosome gel.

The preparation of c, transdermal patch: the arctigenin lipidosome gel of b preparation is evenly coated on the backing layer, be coated with the pressure sensitive adhesive adhered layer around the gel, make transdermal patch, in addition protective layer is compound cuts out with made transdermal patch at last.

The ointment of arctigenin provided by the invention, it comprises arctigenin, solvent, emulsifying agent, antiseptic, transdermal enhancer and thickening agent, described solvent comprises distilled water at least, glycerol and 1, a kind of in the 2-propylene glycol, described emulsifying agent comprises sodium stearate at least, enuatrol, sodium lauryl sulphate, sodium hexadecyl sulfate, sulfated castor oil, a kind of in glyceryl monostearate and the Tween-80, described antiseptic comprises benzalkonium bromide at least, chlorhexidine acetate, sodium benzoate, citric acid, a kind of in methyl hydroxybenzoate and the propyl hydroxybenzoate, described transdermal enhancer is carbamide, and described thickening agent comprises lanoline at least, Cera Flava, liquid paraffin, white vaseline, a kind of in stearic acid and the octadecanol.

The spray of arctigenin provided by the invention contains arctigenin, solvent, cosolvent, antiseptic, carbamide and sodium chloride, described solvent is distilled water, cosolvent is propylene glycol or glycerol, and antiseptic is benzalkonium bromide, chlorhexidine acetate, sodium benzoate, ethyl hydroxybenzoate, methyl hydroxybenzoate or sorbic acid.

Arctigenin external preparation penetration of the present invention is strong, for the synovitis of each joint part specially good effect is arranged all.Clinical practice 300 routine effective percentage are up to more than 70%, and aspect the effective percentage for the treatment of synovitis, arctigenin external preparation treatment group is higher than the effective percentage of Chinese medicinal external application treatment group, has significant significant difference; Aspect onset time, the onset time of arctigenin external preparation treatment group significantly is lower than the Chinese medicinal external application treatment group.This shows that the arctigenin external preparation can be used as the active drug for the treatment of synovitis.

In a word, arctigenin provided by the invention is compared with prior art, has following outstanding advantage:

The first, prior art mostly adopts two or more therapeutic modalities to carry out simultaneously, has just obtained good curative effect and the present invention gives a kind of pharmaceutical preparation of arctigenin, greatly makes things convenient for the patient to use.

The second, this medicine is to extract the arctigenin monomer that obtains from the natural plants Fructus Arctii, compares with traditional external application of Chinese medicine agent, has the advantages such as pharmacologically active is strong, therapeutic efficiency is high, rapid-action, toxicity is low, easy to use.

The specific embodiment

Below further describe the present invention by specific embodiment, the present invention is not limited only to following examples.

The observation of curative effect of embodiment 1 arctigenin treatment synovitis

1. clinical practice data

300 routine patients, women's 180 examples, male's 120 examples.Mean age 58, the course of disease 3~10 years.The patient has that knee pain, bony crepitus, bone tenderness, bone expand, the joint fluid inspection meets osteoarthritis and x-ray is seen the symptoms such as hyperosteogeny formation.

2. Therapeutic Method

2.1 medicine and usage and dosage:

External application of Chinese medicine agent, concrete preparation method is according to CN101721484A embodiment 1, be mixed with by following medicine: Herba Schizonepetae 30g, Radix Saposhnikoviae 30g, Herba Ephedrae 30g, Radix Angelicae Dahuricae 30g, Herba speranskiae tuberculatae 10g, Herba Leonuri 30g, Radix orixae japonicae 30g, Olibanum 30g, Myrrha 30g etc., spread on the affected part, every day twice, sooner or later respectively once.

Arctigenin liniment low dosage, concrete preparation method is according to the embodiment of the invention 2, and the concentration of arctigenin is 10mg/ml, is applied to the affected part, every day twice, sooner or later respectively once.

Arctigenin liniment high dose, concrete preparation method is according to the embodiment of the invention 3, and the concentration of arctigenin is 20mg/ml, is applied to the affected part, every day twice, sooner or later respectively once.

The arctigenin ointment, concrete preparation method is according to the embodiment of the invention 6, and the concentration of arctigenin is 10mg/ml, is applied to the affected part, every day twice, sooner or later respectively once.

The arctigenin spray, concrete preparation method is according to the embodiment of the invention 7, and the concentration of arctigenin is 10mg/ml, is applied to the affected part, every day twice, sooner or later respectively once.

The arctigenin transdermal patch, concrete preparation method is according to the embodiment of the invention 8, and the concentration of arctigenin is 20mg/ml, is affixed on the affected part, once a day.

2.2 untoward reaction emergency processing

If after using this product, aggravation person or other skin lesion person occurs discontinues medication immediately and seeks medical advice.

3. criterion of therapeutical effect (1) clinical recovery: clinical symptom disappearance, joint movement function recover normal, walking and having squatted freely.(2) produce effects: clinical symptom disappearance, function of joint are recovered normally substantially, feel dull pain when only meeting Changes in weather or fatigue.(3) take a turn for the better: arthralgia alleviates, and function of joint is partly recovered.(4) invalid: clinical symptoms and function of joint are treated front without improving.

4. date processing

Record respectively the recovery from illness number, produce effects number, improvement number, invalid number of each treatment group and average onset time (minute, min), each treatment group time of average onset time for obviously alleviating from being administered into the arthralgia symptom wherein.Date processing is as follows: cure rate=recovery from illness number/the type case sum * 100%; Obvious effective rate=produce effects number/the type case sum * 100%; Improvement rate=improvement number/the type case sum * 100%; Inefficiency=invalid number/the type case sum * 100%, effective percentage=(the type case sum-invalid number)/the type case sum * 100%, and applied statistics software SPSS 11.0 carries out the efficient χ of each treatment group 2Check.If χ 2χ 2 0.05,1=3.84, have significant difference with p<0.05.Each treatment group group difference relatively.

5. clinical effectiveness

1) arctigenin liniment provided by the invention reaches more than 90% the synovitis effective percentage, the average onset time of arctigenin liniment low dosage and high dose is respectively 25.5min and 18min, and the patient aggravation and other untoward reaction do not occur after using arctigenin liniment provided by the invention.

2) compare with external application of Chinese medicine agent group, aspect treated effect, arctigenin preparation group all has significant difference (p<0.01); Aspect onset time, arctigenin liniment group, spray group and aerosol group also all have significant difference (p<0.05 or p<0.01).

This further show the arctigenin liniment treatment have aspect the synovitis effective percentage high, to the characteristics that zest is little, onset time is short of skin.The results are shown in Table 1.

The observation of curative effect of table 1 arctigenin treatment synovitis

*Compare p<0.05 with external application of Chinese medicine agent group; *Compare p<0.01 with external application of Chinese medicine agent group.

Owing to having described the present invention according to above preferred embodiment, some is modified and equivalent variations is apparent for those of ordinary skill in the art and comprises within the scope of the present invention.Particularly, described some modification and equivalent variations mainly comprise: in embodiment 1, for a person skilled in the art, can use the arctigenin external preparation of pharmaceutical preparation embodiment preparation partly as tested medicine, the concentration of arctigenin is also done corresponding variation in the positive control medicine simultaneously, and these equivalent variations are apparent and are included in the present invention.

Embodiment 2 arctigenin liniments

Adding distil water is to 100ml, regulates pH value to 7.0 with an amount of 10% sodium hydroxide solution simultaneously.

Preparation technology: at normal temperatures and pressures, weighing arctigenin 1g is dissolved in an amount of distilled water, and the proportioning according to each component in the prescription adds respectively wherein again, i.e. glycerol 10g, carbamide 0.2g, benzalkonium bromide 0.2g, sodium chloride 0.1g.Last adding distil water is to 100ml, and abundant mixing is simultaneously with an amount of 10% sodium hydroxide solution adjusting PH to 7.0.

Embodiment 3 arctigenin liniments

Adding distil water is to 100ml, regulates pH value to 5.0 with an amount of 10% sodium carbonate liquor simultaneously.

Preparation technology is with embodiment 2, and last adding distil water is to 100ml, and abundant mixing is simultaneously with an amount of 10% sodium carbonate liquor adjusting PH to 5.0.

Embodiment 4 arctigenin liniments

Adding distil water is to 100ml, regulates pH value to 6.5 with an amount of 10% sodium carbonate liquor simultaneously.

Preparation technology is with embodiment 2, and last adding distil water is to 100ml, and abundant mixing is simultaneously with an amount of 10% sodium carbonate liquor adjusting PH to 6.5.

Embodiment 5 arctigenin liniments

Adding distil water is to 100ml, regulates PH to 7.0 with an amount of 10% sodium carbonate liquor simultaneously.

Preparation technology is with embodiment 2, and last adding distil water is to 100ml, and abundant mixing is simultaneously with an amount of 10% sodium carbonate liquor adjusting PH to 7.0.

Embodiment 6 arctigenin ointments

Preparation technology: first part recipe quantity arctigenin, stearic acid are dissolved in the water-bath heating, add again white vaseline and be heated to 80 ℃, form oil phase; Residue recipe quantity arctigenin is dissolved in 1,2-PD and an amount of distilled water, then adds carbamide, Tween-80 (Tween 80), benzalkonium bromide, adding distil water is to 1000g, and is heated to 80 ℃, forms water; At last the slow stream of oil phase is added to aqueous phase, the limit edged stirs, until finished product is checked to get in condensation.

Embodiment 7 arctigenin sprays

Adding distil water is to 100ml, regulates pH value to 6.0 with an amount of 10% sodium hydroxide solution simultaneously.

Preparation method: at normal temperatures and pressures, weighing arctigenin 1g is dissolved in an amount of distilled water, and the proportioning according to each component in the prescription adds respectively wherein again, be propylene glycol 10g, carbamide 1g, sodium benzoate 0.01g, sodium chloride 0.01g, last adding distil water fully stirs mixing to 100ml, regulate PH to 6.0 with an amount of 10% sodium hydroxide solution simultaneously, canned, finished product is checked to get in sealing.

Embodiment 8 arctigenin transdermal patches

Preparation technology:

The preparation of a, liposome: take by weighing recipe quantity arctigenin, fabaceous lecithin, cholesterol, vitamin E, dissolving adds diethyl ether; Other gets phosphate buffer, be heated to 40-80 ℃ and keep constant temperature, prepared diethyl ether solution is at the uniform velocity injected buffer under the continuous stirring, continued to stir after ether is waved to the greatest extent supersound process 10-60 minute, make milky arctigenin liposome turbid liquor.

The preparation of b, drug gel: get Carbomer-940, sodium polyacrylate, glycerol, moistening grinds well, in the arctigenin liposome turbid liquor that adding a makes, stirring makes its swelling, add phosphate buffer to 1000mL, an amount of triethanolamine is regulated the rear continuation of suspension PH to 8.0 and is stirred, and makes the arctigenin lipidosome gel.

The preparation of c, transdermal patch: the arctigenin lipidosome gel of b preparation is evenly coated on the backing layer, be coated with the pressure sensitive adhesive adhered layer around the gel, make transdermal patch, in addition protective layer is compound cuts out with made transdermal patch at last.

Embodiment 9 arctigenin gels

Regulate PH to 7.0 with an amount of triethanolamine, and adding distil water is to 1000ml,

Preparation technology: get 30ml glycerol, 16g Carbomer-940,4g laurocapram and put in the mortar and grind well, and add an amount of distilled water, slowly drip an amount of triethanolamine and regulate PH to 7.0, the limit edged stirs, make into gel, add arctigenin 20g mix homogeneously, add distilled water to 1000ml, stir evenly packing and get final product.

Embodiment 10 arctigenin aerosols

Preparation technology: arctigenin, carbamide, the vitamin C of recipe quantity are dissolved in the sterile distilled water, and sand core funnel filters behind the adding ethanol, adds to 1000ml with sterile distilled water, divided dose is canned, sealing-in dosage valve system, dichlorodifluoromethane is injected in pressurization more respectively, and get final product.

Embodiment 11 arctigenin ointments

Preparation technology: the arctigenin of recipe quantity is dissolved with suitable quantity of water, Acritamer 940 is joined in the aqueous solution that contains arctigenin, form low viscous acid solution, stirring is dissolved arctigenin fully, the Tween-80, carbamide, glycerol and the ethyl hydroxybenzoate that add recipe quantity, add water to stirring and dissolving behind the 1000mL, regulate pH value to 7.0 with triethanolamine and get final product.

Claims (5)

1. arctigenin is preparing the purposes for the treatment of in the synovitis medicine.
2. purposes as claimed in claim 1 is characterized in that described arctigenin is external preparation.
3. purposes as claimed in claim 2 is characterized in that described arctigenin external preparation can be liniment, transdermal patch, spray, ointment, gel, aerosol or ointment.
4. purposes as claimed in claim 3 is characterized in that described arctigenin liniment comprises arctigenin, glycerol, carbamide, benzalkonium bromide, sodium chloride and water, and its weight portion is:
5. purposes as claimed in claim 3 is characterized in that described arctigenin transdermal patch comprises backing layer, drug storage layer and adhered layer, and the weight portion of described each component of drug storage layer is:
CN2012103699790A 2011-09-28 2012-09-27 Use of arctigenin in preparing drug for treating synovitis CN103027905A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201110301017.7 2011-09-28
CN201110301017 2011-09-28
CN2012103699790A CN103027905A (en) 2011-09-28 2012-09-27 Use of arctigenin in preparing drug for treating synovitis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN2012103699790A CN103027905A (en) 2011-09-28 2012-09-27 Use of arctigenin in preparing drug for treating synovitis

Publications (1)

Publication Number Publication Date
CN103027905A true CN103027905A (en) 2013-04-10

Family

ID=48015635

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2012103699790A CN103027905A (en) 2011-09-28 2012-09-27 Use of arctigenin in preparing drug for treating synovitis

Country Status (1)

Country Link
CN (1) CN103027905A (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101484179A (en) * 2006-07-03 2009-07-15 信一制药株式会社 Trachelospermi caulis extract composition for the treatment and prevention of inflammatory diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101484179A (en) * 2006-07-03 2009-07-15 信一制药株式会社 Trachelospermi caulis extract composition for the treatment and prevention of inflammatory diseases

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HYO SOOK KANG, ET AL: "Anti-inflammatory activity of arctigenin from Forsythiae Fructus", 《JOURNAL OF ETHNOPHARMACOLOGY》, 31 December 2008 (2008-12-31), pages 305 - 312 *
WEI-JERN TSAI, ET AL: "Arctigenin from Arctium lappa inhibits interleukin-2 and interferon gene expression in primary human T lymphocytes", 《CHINESE MEDICINE》, 25 March 2011 (2011-03-25), pages 1 - 8, XP021097129, DOI: doi:10.1186/1749-8546-6-12 *
于宏: "牛蒡的化学成分与生物活性", 《国外医药 植物药分册》, vol. 22, no. 6, 31 December 2007 (2007-12-31), pages 244 - 247 *
何天佑: "《何氏骨科学》", 30 September 2009, article "风湿性关节炎", pages: 615 *
国家食品药品监督管理局药品审评中心: "《药品技术评价文集,第3辑》", 31 March 2009, article "皮肤给药制剂", pages: 51 *
宋宏春: "《药剂学实验》", 31 December 2010, article "搽剂", pages: 147 *

Similar Documents

Publication Publication Date Title
CN101167847A (en) Traditional Chinese medicinal white spirit preparation for effectively treating skin disease
CN102091309B (en) Pharmaceutical composition for treating bedsore and preparation method thereof
CN100569273C (en) A kind of external Chinese medicine that is used for the treatment of skin tumour, tinea, wart, herpes
CN101214286B (en) Chinese medicine white spirit preparations for effectively treating rheumatic pain diseases
CN100427062C (en) Tibetan medicine for major functions of acute-chronic sprain-contusion, rheumatism, rheumatoid diseases, and its preparing method
CN103845348B (en) 20 (R)-ginsenoside Rg3s application in preparation dysmenorrhea medicine
CN102895460B (en) Traditional Chinese medicine composition for fracture and soft tissue injury
CN101940631B (en) Method for preparing pollen itching-dispelling pain-relieving tincture
CN100493595C (en) Infrared cough relieving paste
CN105148288A (en) Cyclodextrin-and-modified-cyclodextrin-assisted method for extracting effective ingredients of traditional Chinese medicinal materials
CN103961636B (en) Orthopedic disease treatment external application traditional Chinese medicine composition, preparation method and application thereof
CN103845349A (en) Application of 20(R)-ginsenoside Rg3 in preparation of medicines for treating leucoderma
CN102846842B (en) Topical gel for treating rheumatic arthritis
CN104784270A (en) External preparation capable of relieving swelling and pain and preparation method thereof
CN103432244A (en) Composition having acne removing function
CN104758404A (en) Three-snake powder composition for treating autoimmune diseases, and preparation method thereof
CN104258278A (en) Gushangling (for bone injury) spray
CN101181568A (en) Traditional chinese medicine preparation for curing osteoproliferation as well as arthrosis ache
CN102579902A (en) Chinese medicine composition for curing sicca syndrome and preparation method thereof
CN100469388C (en) Chinese medicine for treating femoral head necrosis
CN103877536A (en) Traditional Chinese medicine composition for treating diarrhea as well as preparation and application thereof
CN101961449B (en) Traditional Chinese medicine for treating tinea corporis
CN105920540A (en) Oil capable of activating collaterals and preparation method thereof
CN102389490A (en) Chinese medical ointment matched with meridian moxibustion guide instrument for external application and preparation method thereof
CN101590107B (en) Rhinitis ointment

Legal Events

Date Code Title Description
PB01 Publication
C06 Publication
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20130410

C12 Rejection of a patent application after its publication